Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
Nov 6, 2024 · Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in ...
Novo Nordisk shares jump 8% after Wegovy sales beat …
Nov 6, 2024 · Novo Nordisk added that sales of Wegovy were 79% higher year-on-year in the third quarter, coming in at 17.3 billion Danish kroner. ... The news was taken as a signal that Novo Nordisk's efforts ...
Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar …
Nov 6, 2024 · Novo Nordisk (NYSE:NVO) is stealing the spotlight in the obesity drug market as Wegovy's sales skyrocketed by 76% year-over-year to DKK 38.3 billion, crushing analysts' forecasts. This explosive ...
Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Nov 1, 2024 · (Bloomberg) -- Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and ...
News Details - Novo Nordisk
Jul 25, 2024 · Wegovy® (semaglutide 2.4 mg) is a weight management drug that also reduces the risk of major adverse cardiovascular events (MACE) in people with obesity and cardiovascular disease. The European Medicines Agency (EMA) has adopted a positive opinion for an update of the Wegovy® label based on the SELECT trial data.
News details - Novo Nordisk
Mar 8, 2024 · Wegovy® is the first-and-only medicine to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and heart disease. The FDA approval is based on the SELECT trial, which showed a 20% relative …
News Details - Novo Nordisk
Mar 8, 2024 · Wegovy®, a weight management therapy based on semaglutide, has received FDA approval for reducing the risk of major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease. The approval is based on the SELECT trial, which showed a 20% risk reduction compared to placebo.
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …
News details - Novo Nordisk
PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss …
News Details - Novo Nordisk
Nov 11, 2021 · Wegovy™ is a once-weekly semaglutide 2.4 mg injection that reduces hunger and increases fullness for chronic weight management in adults with obesity or overweight. The European Medicines Agency has adopted a positive opinion for Wegovy™, based on results from the STEP clinical trial programme.
- Some results have been removed